Daily Stock Setups

Trading Outlook for ZymoGenetics Inc. Issued by StockPreacher.com

Posted on: Thu, 12 Nov 2009 06:50:00 EST

Symbols: KG, BMY, ONXX, HGSI, ZGEN

Are you looking to increase your ETF knowledge?

DALLAS, Nov 12, 2009 (GlobeNewswire via COMTEX) --
ZGEN | Quote | Chart | News | PowerRating -- StockPreacher.com announces an investment report featuring ZymoGenetics Inc. (Nasdaq:ZGEN). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.

The full report is available at: http://www.stockpreacher.com/n/ZGEN

Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher

ZymoGenetics Inc. (ZGEN) is a biopharmaceutical company, focuses on the discovery, development, manufacture and commercialization of therapeutic proteins for the treatment of human diseases, including hemostasis, inflammatory and autoimmune diseases, cancer and viral infections. Its products include RECOTHROM, a recombinant thrombin, which is a topical hemostatic agent used for the control of moderate bleeding during surgical procedures. The Company's product candidates in clinical development stages include PEG-IFN-l, a pegylated version of the IFN-l1 protein; IL-21 for the treatment of metastatic melanoma and metastatic renal cell carcinoma; IL-21 monoclonal antibody (mAb) to treat inflammatory diseases; and IL-31 mAb for the treatment of atopic dermatitis and inflammatory diseases.

Message Board Search for ZGEN: http://www.boardcentral.com/boards/ZGEN

In the report, the analyst notes:

"The Company's first internally developed product candidate, RECOTHROM(R) Thrombin, was approved by the U.S. Food and Drug Administration in January 2008 for use as a topical hemostat to control moderate bleeding during surgical procedures and is now being marketed in the United States. Simultaneously, ZGEN entered into a co-promotion agreement with Bayer Healthcare LLC under which Bayer is assisting the Company with the promotion of RECOTHROM in the U.S. for up to four years, ending in March 2012.

"At the beginning of 2009, ZGEN and Bristol-Myers Squibb Company announced a global collaboration for PEG-Interferon lambda, a novel type 3 interferon for the treatment of Hepatitis C, and its related development program. Under the terms of the collaboration, Bristol-Myers Squibb agreed to pay ZymoGenetics an upfront cash payment of $85 million for the development and commercialization rights to PEG-Interferon lambda, and to pay an additional license fee of $20 million in 2009."

To read the entire report visit: http://www.stockpreacher.com/n/ZGEN

StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com

StockPreacher.com Disclosure

StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: StockPreacher

CONTACT:  StockPreacher.com
Jeff Bishop
(469)-252-3505
press@beaconequity.com

For full details on King Pharmaceuticals Inc (KG) KG. King Pharmaceuticals Inc (KG) has Short Term PowerRatings at TradingMarkets. Details on King Pharmaceuticals Inc (KG) Short Term PowerRatings is available at This Link.

For full details on Bristol-Myers Squibb Co (BMY) BMY. Bristol-Myers Squibb Co (BMY) has Short Term PowerRatings at TradingMarkets. Details on Bristol-Myers Squibb Co (BMY) Short Term PowerRatings is available at This Link.

For full details on Onyx Pharmaceuticals Inc (ONXX) ONXX. Onyx Pharmaceuticals Inc (ONXX) has Short Term PowerRatings at TradingMarkets. Details on Onyx Pharmaceuticals Inc (ONXX) Short Term PowerRatings is available at This Link.

For full details on Human Genome Sciences (HGSI) HGSI. Human Genome Sciences (HGSI) has Short Term PowerRatings at TradingMarkets. Details on Human Genome Sciences (HGSI) Short Term PowerRatings is available at This Link.

For full details on Zymogenetics Inc (ZGEN) ZGEN. Zymogenetics Inc (ZGEN) has Short Term PowerRatings at TradingMarkets. Details on Zymogenetics Inc (ZGEN) Short Term PowerRatings is available at This Link.

More News: Market Updates | Stock Alerts | All Trading News

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.